• Roscovitine (Seliciclib): Applied CDK Inhibition in Research

  2026-07-27

  Roscovitine (Seliciclib, CYC202) is a cornerstone tool for precise cell cycle arrest and in vivo tumor growth inhibition. This article delivers actionable protocols, advanced troubleshooting, and experimental strategies—grounded in both hands-on and cheminformatics-backed insights—for maximizing research with this selective CDK inhibitor.

• Antiseptics for Burns: Evidence and Implications for Antibio

  2026-07-26

  The Cochrane review 'Antiseptics for burns' rigorously assesses the comparative effectiveness of antiseptics, including topical antibiotics, in promoting wound healing and preventing infection in burn care. Its findings clarify the nuanced roles of silver dressings and antibiotic regimens, providing high-certainty guidance for researchers and clinicians seeking to optimize antimicrobial strategies in burn management.

• GI 254023X: Precision ADAM10 Inhibitor for Advanced Cell Mod

  2026-07-25

  GI 254023X empowers researchers with highly selective ADAM10 inhibition, enabling robust studies of cell signaling, apoptosis, and vascular integrity. This article delivers actionable workflows, troubleshooting strategies, and comparative insights to maximize the experimental value of GI 254023X in disease modeling.

• Cuproptosis Gene Signature Refines Glioma Subtyping and Ther

  2026-07-24

  This study introduces a cuproptosis-related gene signature that enables precise molecular subtyping of gliomas and predicts their sensitivity to copper-dependent cell death inducers. The findings offer new mechanistic insights into copper homeostasis in glioma progression and support the development of more targeted therapeutic strategies.

• Dimetridazole Potentiates Cefotaxime Against MDR E. coli

  2026-07-24

  Wei et al. demonstrate that dimetridazole, a 1,2-dimethyl-5-nitroimidazole, synergistically enhances cefotaxime efficacy against multidrug-resistant E. coli by disrupting membrane integrity and altering fatty acid composition. These findings highlight a promising approach for reviving cephalosporin activity against resistant pathogens through membrane-targeted combination therapy.

• IWP-L6: Precision Porcupine Inhibitor for Wnt Pathway Modula

  2026-07-23

  IWP-L6 offers sub-nanomolar Porcupine inhibition, enabling robust and reproducible control over Wnt signaling in advanced metabolic and developmental biology assays. With proven efficacy in both in vitro and in vivo systems, this APExBIO compound streamlines Wnt pathway interrogation and troubleshooting for high-impact research.

• Dose-Dependent Host Responses to Porcine Deltacoronavirus In

  2026-07-23

  This study elucidates how porcine deltacoronavirus (PDCoV) infection triggers dose-dependent innate immune responses in intestinal epithelial cells, revealing that higher viral loads induce broader transcriptional remodeling and heightened inflammation. The findings highlight STAT1 and its downstream ISGs as critical antiviral effectors, offering mechanistic insight for future immunomodulatory interventions.

• Host-Directed Control of M. tuberculosis via GSK3 Inhibition

  2026-07-22

  A recent iScience study demonstrates that inhibiting glycogen synthase kinase 3 (GSK3) in macrophages restricts intracellular Mycobacterium tuberculosis (Mtb) growth, offering a host-directed therapy (HDT) alternative to traditional antibiotics. This approach highlights the potential of targeting host signaling pathways to combat multi-drug resistant tuberculosis and challenges conventional antimicrobial paradigms.

• Dissecting Metabolite Regulation of TET2 via Biochemical and

  2026-07-22

  Zhang et al. (2025) introduce a robust protocol integrating biochemical assays with STD NMR spectroscopy to systematically validate metabolite binding and regulatory effects on human TET2 dioxygenase. This approach enables precise identification of TET2 activators and inhibitors, advancing our mechanistic understanding of the interface between cellular metabolism and epigenetic regulation.

• Gefitinib (ZD1839): Precision EGFR Pathway Modulation in Ski

  2026-07-21

  Explore how Gefitinib (ZD1839) advances EGFR signaling pathway inhibition, not only in cancer models but also in skin barrier research. This article uniquely bridges oncology and dermatology, revealing novel research opportunities.

• Alternariol: Mechanistic Leverage for Translational Mycotoxi

  2026-07-21

  This article provides translational researchers with a mechanistic and strategic framework for leveraging Alternariol (AOH) in mycotoxin research. Integrating fresh omics-driven insights, the piece details AOH’s molecular effects—spanning cytochrome P450 metabolism, apoptosis induction, and hepatic fibrosis modeling—while offering practical workflow guidance and positioning APExBIO’s Alternariol as a gold-standard tool. Competitive benchmarking, protocol parameters, and a forward-looking outlook distinguish this resource as a bridge between foundational science and impactful translational applications.

• Mifepristone (RU486): Redefining Hormone Antagonism for Tran

  2026-07-20

  Explore how Mifepristone (RU486) is revolutionizing cancer and reproductive research by targeting progesterone receptor pathways and enabling next-generation translational models. This thought leadership article distills mechanistic insights, protocol guidance, and strategic recommendations for translational researchers seeking to harness the full potential of RU486—bridging the gap from bench to bedside.

• Brassinolide: Translational Bridges from Plant Growth to Can

  2026-07-20

  This thought-leadership article explores how Brassinolide—a canonical brassinosteroid and potent apoptosis inducer—serves as a mechanistic and strategic bridge between plant biology and disease research. Leveraging recent advances in structure-activity relationships and translational assay design, we offer guidance for researchers seeking reproducible, high-impact outcomes in both fundamental and applied settings.

• MK-8745: Applied Workflows for Aurora A Inhibition in Cancer

  2026-07-19

  MK-8745 stands out as a potent and selective Aurora A inhibitor, enabling precise cell cycle modulation and apoptosis induction in diverse cancer models. Its robust performance, even in chemoresistant or high-risk phenotypes, empowers researchers to dissect mitotic regulation and therapeutic responses with confidence.

• Cucurbitacin I (JSI-124): Advanced STAT3 Inhibition Workflow

  2026-07-18

  Cucurbitacin I (JSI-124) delivers potent, selective STAT3 pathway inhibition, empowering precise modeling of tumor biology and therapy response. This guide translates reference-backed workflows and troubleshooting strategies into actionable steps for optimizing cancer research with APExBIO's trusted compound.

451 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page